Login / Signup

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.

Michael L WangTanya SiddiqiLeo I GordonManali KamdarMatthew LunningAlexandre V HirayamaJeremy S AbramsonJon ArnasonNilanjan GhoshAmitkumar MehtaCharalambos AndreadisScott R SolomonAna KosticChristine DehnerRicardo EspinolaLily PengKen OgasawaraAmy ChattinLaurie EliasonMaria Lia Palomba
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Liso-cel demonstrated high CR rate and deep, durable responses with low incidence of grade ≥3 CRS, NE, and infections in patients with heavily pretreated relapsed/refractory MCL, including those with high-risk, aggressive disease.
Keyphrases
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • multiple myeloma
  • diffuse large b cell lymphoma
  • hodgkin lymphoma
  • risk factors
  • clinical trial
  • double blind